Comparison of the effect of two human milk fortifiers on clinical outcomes in premature infants by Thoene, Melissa et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Journal Articles: Nebraska Medicine Nebraska Medicine 
1-2014 
Comparison of the effect of two human milk fortifiers on clinical 
outcomes in premature infants 
Melissa Thoene 
The Nebraska Medical Center, mthoene@nebraskamed.com 
Corrine K. Hanson 
University of Nebraska Medical Center, ckhanson@unmc.edu 
Elizabeth Lyden 
University of Nebraska Medical Center, elyden@unmc.edu 
Laura Dugick 
The Nebraska Medical Center, ldugick@nebraskamed.com 
Leslie Ruybal 
University of Nebraska Medical Center, leslie.ruybal@unmc.edu 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unmc.edu/tnmc_articles 
 Part of the Dietetics and Clinical Nutrition Commons, Medical Nutrition Commons, and the Pediatrics 
Commons 
Recommended Citation 
Thoene, Melissa; Hanson, Corrine K.; Lyden, Elizabeth; Dugick, Laura; Ruybal, Leslie; and Anderson-Berry, 
Ann, "Comparison of the effect of two human milk fortifiers on clinical outcomes in premature infants" 
(2014). Journal Articles: Nebraska Medicine. 1. 
https://digitalcommons.unmc.edu/tnmc_articles/1 
This Article is brought to you for free and open access by the Nebraska Medicine at DigitalCommons@UNMC. It 
has been accepted for inclusion in Journal Articles: Nebraska Medicine by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
Authors 
Melissa Thoene, Corrine K. Hanson, Elizabeth Lyden, Laura Dugick, Leslie Ruybal, and Ann Anderson-Berry 
This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/tnmc_articles/1 






Comparison of the Effect of Two Human Milk Fortifiers on 
Clinical Outcomes in Premature Infants 
Melissa Thoene 1, Corrine Hanson 2, Elizabeth Lyden 3, Laura Dugick 1, Leslie Ruybal 4 and  
Ann Anderson-Berry 4,* 
1 Newborn Intensive Care Unit, Nebraska Medical Center, Omaha, NE 68198, USA;  
E-Mails: mthoene@nebraskamed.com (M.T.); ldugick@nebraskamed.com (L.D.) 
2 School of Allied Health Professionals, University of Nebraska Medical Center,  
984045 Nebraska Medical Center, Omaha, NE 68198-4045, USA; E-Mail: ckhanson@unmc.edu 
3 College of Public Health, University of Nebraska Medical Center, 984375 Nebraska Medical 
Center, Omaha, NE 68198-4375, USA; E-Mail: elyden@unmc.edu 
4 Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198-2185, USA; 
E-Mail: leslie.ruybal@unmc.edu 
* Author to whom correspondence should be addressed; E-Mail: alanders@unmc.edu;  
Tel.: +1-402-559-6750. 
Received: 26 October 2013; in revised form: 17 December 2013 / Accepted: 20 December 2013 /  
Published: 3 January 2014 
 
Abstract: The use of human milk fortifiers (HMF) helps to meet the high nutritional 
requirements of the human milk-fed premature infant. Previously available powdered 
products have not met the protein requirements of the preterm infant population and many 
neonatologists add powder protein modulars to help meet protein needs. The use of 
powdered products is discouraged in neonatal intensive care units (NICU) due to concern 
for invasive infection. The use of a commercially available acidified liquid product with 
higher protein content was implemented to address these two concerns. During the course 
of this implementation, poor growth and clinically significant acidosis of infants on 
Acidified Liquid HMF (ALHMF) was observed. The purpose of this study was to quantify 
those observations by comparing infant outcomes between groups receiving the ALHMF 
vs. infants receiving powdered HMF (PHMF). A retrospective chart review compared 
outcomes of human milk-fed premature infants <2000 g receiving the ALHMF  
(n = 23) and the PHMF (n = 46). Infant growth, enteral feeding tolerance and provision, 
and incidence of necrotizing enterocolitis (NEC), metabolic acidosis, and diaper dermatitis 
were compared between the two groups. No infants were excluded from this study based 
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on acuity. Use of ALHMF resulted in a higher incidence of metabolic acidosis (p = 0.002). 
Growth while on HMF as measured in both g/kg/day (10.59 vs. 15.37, p < 0.0001) and  
in g/day (23.66 vs. 31.27, p = 0.0001) was slower in the ALHMF group, on increased mean 
cal/kg/day (128.7 vs. 117.3, p = 0.13) with nearly twice as many infants on the ALHMF 
requiring increased fortification of enteral feedings beyond 24 cal/ounce to promote 
adequate growth (48% vs. 26%, p = 0.10). Although we were not powered to study NEC as 
a primary outcome, NEC was significantly increased in the ALHMF group. (13% vs. 0%,  
p = 0.03). Use of a LHMF in an unrestricted NICU population resulted in an increase in 
clinical complications within a high-acuity NICU, including metabolic acidosis and poor 
growth. Although further research is needed to assess outcomes among infants with a 
variety of clinical acuities, gestational ages, and weights to confirm these findings, based 
on this experience, caution is urged to avoid potential risks. 
Keywords: prematurity; human milk; fortifier; infant feeding; growth; acidosis 
 
1. Introduction 
Infants born prematurely have increased nutrient needs compared to those born at term [1–3]. 
Nutrition-related goals for premature infants aim to mimic fetal nutrient accretion and growth  
in utero [4], yet many develop extrauterine growth restriction (EUGR) [5]. 
Despite the availability of customized, nutrient-dense enteral formulas, the American Academy of 
Pediatrics strongly supports the use of human milk for premature infants [6]. However, unfortified 
human milk remains inadequate to meet the high nutrient requirements of premature infants [1,4,7]. 
Provision of unfortified human milk has subsequently been linked to suboptimal growth (development 
of EUGR or growth < 15 g/kg/day), reduced bone density leading to osteopenia of prematurity and a 
clinical diagnosis of rickets, and the secondary consequences of each [1,4]. 
The use of commercial human milk fortifiers (HMF) allows for a more optimal provision  
of essential nutrients to meet premature infant requirements [1,4,7]. Macronutrient recommendations  
for low birth weight premature infants vary, but consensus goal ranges suggest enteral intake  
of 110–120 cal/kg/day and 3.4–4.4 g protein/kg/day [1]. Protein is specifically emphasized, as early 
and higher provisions promote more desirable growth and clinical outcomes [8,9]. The use of HMF 
has been shown to be both safe and effective in improving growth and nutrition status of premature 
infants compared to unfortified human milk [7,10,11]. In recent years the use of HMF with additional 
powdered protein modular has been presented as a method of supplying the preterm infant with the 
recommended amount of enteral protein to provide improved linear growth and neurodevelopmental 
outcomes [12,13]. 
Human milk fortifiers have primarily been available in powder form, although the United States 
Food and Drug Administration discourages the use of powdered forms in the neonatal intensive care 
units (NICU) secondary to contamination risk [14]. They additionally advise that “alternatives to 
powdered forms should be chosen when possible” [14]. To comply with this recommendation and 
achieve improved protein intake, The Nebraska Medical Center (TNMC) NICU changed standard 
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human milk fortification practices with a powdered product when an acidified liquid HMF (ALHMF) 
with improved protein delivery became available. However, in the four months following our initial 
use of the ALHMF, clinical observations of infants receiving the ALHMF suggested an increased 
feeding intolerance, increased incidence of metabolic acidosis, poor growth, and a need for higher 
caloric densities of enteral feedings to promote adequate growth. Due to our concern for patient 
outcomes, use of the ALHMF was discontinued. The purpose of this study is to objectively quantify 
these clinical observations by comparing outcomes of infants receiving the ALHMF to those receiving 
the originally-used PHMF. Our study also looked to identify potential risk factors for the development 
of the observed clinical complications, as previous research evaluating the ALHMF also documented 
changes in pH and CO2 when compared to a powder HMF (PHMF) [15]. 
2. Patients and Methods 
2.1. Participants and Study Design 
The institutional review board at the University of Nebraska Medical Center (Omaha, NE, USA) 
approved this study. Data was retrospectively collected from inpatient electronic medical records of all 
infants admitted to the NICU, between October 2009 and July 2011, if they met the following 
inclusion criteria: birth weight (BW) < 2000 g, received enteral feedings as fortified maternal breast 
milk during NICU stay, and remained in the NICU ≥ 14 days. Exclusion criteria included infants with 
congenital abnormalities or conditions that significantly inhibited growth, such as Trisomy 13. No 
infants were excluded based on clinical acuity. After extensive chart review, 69 infants were eligible 
for the study. 
2.2. Comparison and Use of Human Milk Fortifiers 
Maternal breast milk (MBM) was fortified according to manufacturer directions. Ingredient and 
estimated nutrient compositions of fortified preterm human milk were obtained from online nutritional 
references [16,17]. Table 1 provides a composition comparison for key nutrients and ingredients. 
Table 1. Comparison of ingrediants and key nutrients using powder and liquid HMF. 
24-Calorie-Per-Ounce Fortified Premature Human Milk [16,17] 
Per 100 mL Powder HMF Liquid HMF 
Protein (g) 2.35 3.2 
Iron (mg) 0.46 1.85 
Calcium (mg) 138 141 
Phosphorus (mg) 78 78 
Vitamin D (IU) 119 200 
pH - 4.7 
Primary Fortifier 
Macronutrient Ingredients
nonfat milk, whey protein 
concentrate, corn syrup solids, 
medium-chain triglycerides 
(MCT oil) 
water, whey protein isolate hydrolysate 
(milk), medium chain triglycerides  
(MCT oil), vegetable oil  
(soy and high oleic sunflower oils) 
-: Information not avaliable. 
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Enteral feedings are initiated in this NICU within the first one to three days of life with Human 
Milk (MBM as available or donor milk form the Milk Bank of Austin) at 20 mL/kg/day, trophic 
feedings are continued for three to five days at the discretion of the attending neonatologist, and  
then feedings are advanced daily by 20 mL/kg/day with human milk fortification beginning at  
80–100 mL/kg/day enteral volume. A protein modular is utilized to improve protein intake to 
approximately 4 g/kg/day enteral protein once caloric density is 24 kcal/oz. While using the ALHMF, 
no additional protein modular was utilized. There were no other nutrition differences during the two time 
periods. Nutrition is managed closely per unit protocol and is very consistent from provider to provider. 
According to unit policy, infants receiving the PHMF also received supplementation with a protein 
modular to provide approximately 4 g protein/kg/day when fed at goal volumes. 
Sole use of the ALHMF was initiated on April 1, 2011. Infants receiving the PHMF before this date 
of fortification change were included in the control group (PHMF, n = 46). Infants receiving the 
ALHMF following this date were included in the study group (ALHMF, n = 23). Infants transitioned 
from the PHMF to the LHMF on the date of fortification change were excluded. 
2.3. Data Collection 
Four investigators familiar with the electronic medical record and NICU terminology obtained all 
data in a consistent predetermined manner. Collected information was reviewed for accuracy and 
corrected if an electronic error occurred. All available information on each infant was included in the 
analysis and is displayed in the tables. 
2.4. Demographics 
Demographic information was collected for all infants including gender, gestational age at birth and 
discharge, and day of life (DOL) at discharge. Additional clinical outcomes were collected including 
the presence of bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), intraventricular 
hemorrhage (IVH), necrotizing enterocolitis (NEC), diaper dermatitis, and death. Treatment 
requirements were coded similarly if an infant required: oxygen at 36 weeks estimated gestational age 
(EGA), ROP procedure, IVH shunt, Avastin treatment, Dexamethasone use, and Bicitra use. ROP 
stage, IVH grade, and number of days of Dexamethasone use were included if available. 
2.5. Anthropometrics 
Infants were weighed daily on a gram scale, and head circumference and length (centimeters)  
were recorded weekly by nursing staff using a measuring tape. Fenton growth curve percentile  
rankings [18,19] were electronically plotted for each recorded anthropometric measurement. Weight, head 
circumference, and length measurements with associated Fenton percentile rankings were taken for 
infants at birth and at 36 weeks EGA, if available. 
2.6. Nutrition 
Enteral feeding data collected included day of life (DOL) enteral feedings were initiated, DOL full 
enteral feedings were reached (with a discontinuation of parenteral nutrition support), and the number 
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of times enteral feedings were held (not secondary to preparation for a procedure). Maximum caloric 
density and number of days on enteral feedings >24 cal/ounce were collected for infants requiring 
caloric densities higher than the standard 24 cal/ounce to promote adequate growth. 
Daily average provision of calories and protein (g) per kg body weight were calculated for infants 
in each group if they received ≥50% of enteral feedings as fortified MBM during NICU stay. These 
averages were taken when fortified enteral feedings reached a minimum of 140 mL/kg/day until either 
daily intake was consistently less than this amount, the infant was changed to unfortified MBM, or the 
infant received greater than 50% infant formula. Growth and nutrition was evaluated for the groups 
comparing only growth during the period where the infant received ≥50% of enteral feedings as 
fortified MBM. An electronic medical system (Intuacare®: Omaha, NE, USA) contained protein 
references for breast milk and specified enteral formulas and caloric density. Nursing staff documented 
daily intake of breast milk or specified enteral formulas, thus, daily calorie and protein provision per 
kg of body weight were electronically calculated using the daily-recorded weight. The electronic 
medical system also calculated the percentages of MBM vs. infant formula received according to  
nursing documentation. 
2.7. Laboratory Measurements 
Maximum creatinine, maximum blood urea nitrogen (BUN) level, maximum base deficit value, 
maximum calcium level, and lowest carbon dioxide (CO2) lab values were collected, if available, after 
DOL 14 and DOL 30 for all infants. Values were not collected before DOL 14 to eliminate those 
reflective of parenteral nutrition support and unfortified enteral feedings. Phosphorus and pH were not 
consistently nor routinely obtained in this patient population and were therefore not collected in this 
retrospective study. 
2.8. Data Analysis 
Descriptive statistics were displayed for all variables by type of milk (powder vs. liquid) given. The 
Wilcoxon rank sum test was used to compare continuous data between the milks groups. Associations 
of categorical variables were assessed with the Fisher’s exact test. A p-value ≤ 0.05 was considered 
statistically significant. To assess the difference in growth patterns between infants given powder and 
infants given liquid, a mixed effects model was used. We included random slopes and intercepts for 
each subject to capture individual growth pattern as well as fixed effects for group and day and a group 
day interaction term. A significant interaction of day and group indicates differing growth patterns 
based on group. Growth Velocity (GV) was calculated using Equation 1 [20]. 
GV = [1000 × ln(Wn/W1)]/(Dn − D1) (1)
3. Results 
There were 46 infants in the PHMF group (21 males, 25 females) and 23 infants in the ALHMF 
group (13 males, 10 females) (p = 0.45). Additional baseline characteristics were not statistically 
significant between the two groups, as shown in Table 2. Enteral feeding data, growth and analyzed lab 
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values are displayed in Table 3. Clinical outcomes are displayed in Table 4. ROP stage, IVH grade, and 
number of days of Dexamethasone use were not statistically significant and are not included in Table 4. 
Table 2. Baseline characteristics of the subjects. 
Variable 
PHMF ALHMF 
p-value n Mean SD (±) n Mean SD (±) 
CGA at Birth 46 29.5 3.0 23 30.3 2.5 0.21 
Birth Weight (g) 46 1293.7 407.5 23 1437.3  375.6 0.13 
Birth Weight Percentile 46 31.4 24.7 23 36 26.5 0.82 
Weight at 36 Weeks CGA (g) # 44 2245.9 450.72 18 2071.2 367.4 0.17 
Weight Percentile at 36 Weeks CGA # 44 18.6 24.4 18 10.3 13.8 0.22 
HC at Birth (cm) 46 27.2 3.4 22 27.9 2.1 0.19 
HC Percentile at Birth 46 29.9 23.1 22 33.6 26.3 0.7 
HC at 36 Weeks CGA (cm) # 42 32.5 2.6 19 31.9 1.5 0.37 
HC Percentile at 36 Weeks CGA # 42 38.8 30.7 19 31.4 24.6 0.5 
Length at Birth (cm) 46 38.6 3.9 21 40.4 2.8 0.07 
Length Percentile at Birth 46 31.4 24.6 22 32.8 21.9 0.68 
Length at 36 Weeks CGA (cm) # 42 44.2 3.3 19 43.5 4.6 0.44 
Length Percentile at 36 Weeks CGA # 42 17.3 22.3 19 21.3 28.1 0.93 
# Growth at these time points represents nutrition delivery throughout hospitalization not just breast milk with 
PHMF and ALHMF. 
Table 3. Enteral feeding, growth and laboratory data. 
Variable 
PHMF ALHMF p-ValueN Median N Median 
Average Daily Provision of Protein per kg Weight 42 3.9 18 4.3 0.0014 
CO2 Minimum after DOL 14 33 23 16 18.5 0.002 
CO2 Minimum after DOL 30 23 25 8 20 0.002 
Growth Velocity (g/kg/day) while on HMF 46 15.37 21 10.59  <0.0001
Growth (g/day, while on HMF) 46 31.27 21 23.66 0.0001 
DOL Enteral Feedings Started 46 3.0 22 1.1 0.12 
Calcium Maximum 34 10.3 16 10.45 0.17 
BUN Maximum after DOL 14 33 18 16 20 0.28 
BUN Maximum after DOL 30 23 18 8 16 0.91 
Creatinine Maximum 46 0.92 22 0.9 0.52 
Table 4. Clinical outcomes. 
Variable 
PHMF LHMF p-Value n (%) n (%) 
NEC 0 (0%) 3 (13%) 0.03 
ROP 16 (35%) 3 (13%) 0.09 
ROP Procedure 3 (7%) 2 (9%) 1.00 
IVH (any) 18 (39%) 4 (17%) 0.10 
Dexamethasone Treatment 9 (20%) 1 (5%) 0.15 
Bicitra Treatment 0 (0%) 1 (5%) 0.31 
Death 0 (0%) 1 (4%) 0.33 
Diaper Dermatitis 5 (11%) 4 (18%) 0.46 
BPD 9 (20%) 3 (14%) 0.74 
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3.1. Safety and Clinical Outcomes 
Mean lowest CO2 lab values (collected while infants were enterally feeding and not acutely ill) 
were significantly lower in the ALHMF group compared to the PHMF group after both DOL 14  
(18.5 vs. 23 mmol/L, p = 0.002) and DOL 30 (20 vs. 25 mmol/L, p = 0.002). Lowest CO2 lab values 
after DOL 14 are displayed comparatively in Figure 1. Lowest values after DOL 30 are displayed 
similarly in Figure 2. Maximum BUN and creatinine levels were similar between the two fortifier 
groups and were not statistically significant. All other analyzed lab values were not statistically 
different. All laboratory data in this retrospective study was obtained for clinical purposes regardless 
of the fortifier group. 
Incidence of NEC (a variable we were not powered to evaluate) was significantly higher in the 
ALHMF group compared to the PHMF group (13% vs. 0%, p = 0.03). 
Figure 1. CO2 levels between groups after Day of Life 14. The lowest CO2 levels after 
DOL 14 were collected from metabolic panels. The mean level in the powder group  
was 23, the mean level in the liquid group was 18.5. Laboratory clinical reference range  
22–32 mmol/L. The difference is statistically significant (p = 0.002). 
 
Figure 2. CO2 levels between groups after Day of Life 30. The lowest CO2 levels after 
DOL 30 were collected from metabolic panels. The mean level in the powder group  
was 25, the mean level in the liquid group was 20. Laboratory Clinical reference range  
22–32 mmol/L. The difference is statistically significant (p = 0.002). 
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3.2. Enteral Nutrition and Growth 
Growth was significantly different between the two groups as measured in g/kg/day and is 
described in Figure 3. Infant growth as measured in g/day from birth to 36 weeks EGA was 23.7 in the 
PHMF group and 18.8 in the LHMF group (p = 0.057). There were no statistically significant 
differences in the length of time to full feedings or the number of times that feedings were held that 
could account for the difference in growth rates between the two groups. 
Figure 3. The growth pattern of infants receiving powder differs from the growth pattern 
of infants receiving liquid on fortified feed days. The plot shows the growth pattern for 
each infant and the fitted line by group. Based on the plot, infants on powder grow at a 
faster rate than infants receiving liquid. Evaluation of growth in gm/kg/day for the days 
infants were fed fortified breast milk, based on the mixed effects model, shows a 
significant interaction between day and group (p = 0.0022). Truncating the analysis at  
45 days did not attenuate the results. 
 
Daily average protein/kg/day provision was higher in the ALHMF group compared to the PHMF 
group (4.3 vs. 3.9 g, p = 0.0014). Mean enteral calorie provisions in the ALHMF group were higher 
than in the PHMF group, 117.3 kcal/kg/day in the PHMF group as compared to 128.7 kcal/kg/day for 
infants in the ALHMF group (p = 0.057). A higher proportion of infants in the ALHMF group required 
increased caloric density of feedings >24 cal/ounce as compared to infants in the PHMF group,  
(48% vs. 26%, p = 0.10). While this did not reach a statistical difference, clinically this was notable. 
4. Discussion 
To our knowledge, we are the first study to date to report our clinical findings of increased 
complications with the use of ALHMF in a Level IIIc clinical setting. In our retrospective analysis of 
acidosis, growth, and clinical outcomes in NICU infants fed with human milk fortified with LHMF 
and PHMF we found significant acidosis and poor growth in the infants receiving LHMF. These 
findings were very consistent with our clinical impressions during our clinical use of the LHMF. We 
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primary outcome to evaluate NEC, we strongly encourage cautious further evaluation of the product in 
the clinical setting with regards to this serious outcome. 
A key difference in the ALHMF as compared to the PHMF is the acidification process required for 
sterilization. This difference is likely to explain the increased complications seen in the ALHMF 
group. The preterm infant’s inability to buffer this acid load likely led to an increase in clinical 
complications including acidosis, poor growth, and, possibly, NEC. 
4.1. Acidosis 
There was a higher incidence of clinically significant metabolic acidosis in the ALHMF group, with 
one infant requiring treatment with Bicitra. No infants in the PHMF group required Bicitra treatment, 
even with twice as many patients in this group. Premature infants are susceptible to metabolic  
acidosis [21] and renal tubular acidosis. However, these imbalances of acid base status should begin to 
normalize after the first weeks of extrauterine life [21]. Considering similar baseline characteristics, 
we hypothesize additional enteral acid load was a potential contributor to this increased incidence of 
metabolic acidosis in the LHMF group. 
Premature infants are at risk for developing metabolic acidosis secondary to immature  
metabolic processes, a lower renal capacity to adequately excrete acid, and higher urinary losses of  
bicarbonate [2,4,22]. Quantity of protein may affect metabolic processes; however the median daily 
average protein provisions for each fortifier group were within the currently recommended ranges [1]. 
No clearly defined amount for maximum protein provision exists, however, it is suggested that intakes 
greater than 6 g/kg/day are poorly tolerated [2]. Maximum daily average protein provisions for both 
groups were below this level. Another reference states that protein provisions greater than 5 g/kg/day 
may cause azotemia [1], but each group had intakes below this value, and maximum BUN and 
creatinine levels were not different in the two fortifier groups. Having increased protein intake in the 
PHMF group as well as the ALHMF group helps to illuminate that increased protein content in the 
ALHMF was not likely the cause of the adverse outcomes. 
We question if the acidification sterilization process of the ALHMF may contribute to this acidosis 
in some fragile premature infants. Our patient population included in this study was not limited by 
respiratory acuity, as was the population in the Moya et al. paper [23]. We hypothesize that our more 
inclusive population of both healthy infants and more fragile infants who may have less respiratory 
stability decreases their capability to buffer the acid load provided in the ALHMF resulting in clinical 
acidosis in some cases requiring medical therapy. It may be unwise in a fragile preterm infant 
population to minimize the clinical significance of the metabolic acidosis noted in the ALHMF groups 
in our study, the study conducted by Moya et al. [24], who reported that infants fed the ALHMF had 
significantly lower pH (at day six), bicarbonate (at day six and 14), and CO2 (at day 14 and 28), and 
significantly higher chloride (at day 14 and 28). Additionally, in an abstract evaluating 100 infants,  
50 fed with ALHMF and 50 fed with PHMF, published by Cibulskis et al., from Saint Louis 
University at the 2013 AAP_NCE, similar metabolic acidosis is described in this patient population 
(54% ALHMF vs. 10% PHMF, p = 0.0001) [25]. As reported in their abstract, this grouptreated the 
acidosis as if it were clinically significant, discontinuing ALHMF on 21/50 patients due to a clinical 
diagnosis of acidosis [25]. 
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4.2. Enteral Nutrition and Growth 
Infants in the PHMF group received a mean daily calorie intake of 117.3 kcal/kg/day as compared 
to infants in the ALHMF group who received a mean calorie intake of 128.7 kcal/kg/day. Infants in the 
ALHMF group also received a median of 0.4 g protein/kg/day more than the infants in the PHMF 
group. Despite higher protein and calorie provisions in the LHMF group, growth during the HMF 
period was slower between the two groups as evaluated by several methods: in a mixed effects model 
evaluated in g/kg/day (p = 0.002), in g/day (p = 0.0001), and by growth velocity in g/kg/day  
(p < 0.0001). Noted also, is that ALHMF infants experienced an additional decrease of 10 growth 
curve percentiles for weight from birth to 36 weeks EGA when compared to infants in the PHMF 
group (growth at 36 weeks is representative of nutrition delivery that is not limited to the period 
evaluated on PHMF and ALHMF). As Dexamethasone use inhibits growth in premature infants [4], 
we further note that fewer infants in the ALHMF group (5%) compared to the PHMF group (20%) 
required this drug for clinical treatment (p = 0.15). 
Maintaining appropriate growth in this patient population was a high priority, so infants with 
suboptimal growth were fed increased caloric density feedings above 24 cal/oz. Though not 
statistically significant, a higher proportion of infants in the ALHMF group (48%) required caloric 
densities greater than 24 cal/ounce when compared to the PHMF group (26%). Had those 48% of 
infants in the ALHMF group not been prescribed increased caloric densities due to clinical 
observations of poor growth differences in growth throughout the hospitalization would likely have 
been larger between the PHMF groups and ALHMF groups. The statistical significance in infant 
growth as noted in g/kg/day is seen in spite of the high priority our unit takes in maintaining optimal 
growth and the subsequent aggressive adjustment of caloric density to achieve desired results. This 
was ultimately the reason 26% of infants receiving ALHMF were transitioned to receive the PHMF 
once the ALHMF use was discontinued in the NICU. 
Not only are these growth effects consistent with the findings of Moya et al., they raise further 
questions [24]. Moya et al., reported no significant differences in rate of weight gain or head 
circumference growth between infants fed this same ALHMF and infants fed a PHMF, even though 
the human milk fortified with ALHMF contained 23% more protein (3.2 vs. 2.6 g protein/100 mL 
fortified preterm human milk) [24]. In our study, even though we compensated for the difference in 
protein content so that protein intake was similar, there was still poorer growth in infants fed ALHMF. 
At least part of the inability of the additional protein to improve growth may be due to the acidosis 
noted above. It is well-known that infants with metabolic acidosis hyperventilate, as the expiration of 
CO2 drives the elimination of H
+ ions through the bicarbonate buffering system. What is less well 
recognized is that protein catabolism can also be utilized to decrease acidity by the elimination of H+ 
ions through the urinary excretion of NH4
+. Acidosis reduces protein synthesis in rats [26] and leads to 
protein catabolism in humans [27]. 
4.3. NEC 
No infants in PHMF group developed NEC compared to 13% in the ALHMF group. Reasons for 
these occurrences remain unclear, as similar prevention strategies were followed for each group. 
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Previous implementation of aggressive nutrition practices in our unit demonstrated improved feeding 
tolerance and clinical outcomes, with no increased incidence of NEC [12]. These nutrition practices 
remained unchanged during the study period, and no additional clinical practices were implemented 
concurrent with the change in human milk fortification. Slow rate of enteral feeding advancement 
remained consistent between both groups, as evidenced by no statistically significant differences in 
length to full enteral feedings. No changes in brand or caloric density of premature infant formula were 
made, and infant formula was utilized equally in both groups if no MBM was available. As no 
additional practice changes were implemented during this study period, we can neither confirm nor 
exclude use of the ALHMF as a contributor to these occurrences of NEC. Although this study was not 
powered to detect NEC based on historical incidence in our unit with rates over the last five years 
ranging from 2% to 5% from our Vermont Oxford Network data, one should consider that significant 
differences with small sample sizes may either reflect coincidental effects due to sample size, or may 
be due to a real difference that is unexpectedly large. 
4.4. Metabolic Acidosis 
Literature suggests that premature infant formulas contain a high renal acid load, though human 
milk contains less [2,21]. Research has additionally demonstrated that the composition of infant 
formulas may affect the urinary pH and nutrient excretion of premature infants [21,22]. It is further 
proposed that high renal acid loads contribute to maximum renal acid stimulation (urine pH < 5.4) [28] 
in premature infants with immature renal function. Previous research studies have demonstrated that 
infants with metabolic acidosis or maximum renal acid stimulation exhibit decreased growth [28,29]. 
This may also result in an increase in urinary sodium excretion [24,29] and a decrease in nitrogen 
assimilation [30]. Blood sampling for acid-base indicators may not be significantly abnormal in the 
presence of maximum renal acid excretion [22,28]. However, CO2 values may trend low [28], which 
was clearly observed among infants in the ALHMF group (p = 0.002). 
4.5. Summary 
Our results showing increased acidosis in the ALHMF group raise further concerns with use of the 
ALHMF, as infants with metabolic acidosis may experience altered nutrient metabolism [28,31] and 
decreased bone mineralization [32], leading to poor growth and osteopenia of prematurity. 
Poor growth in the ALHMF group may also be attributed to changes to the nutrient content of the 
milk caused by acidification as described by Erickson et al. [23]. This group reported significant 
changes in acidified breast milk, including decreased total protein content, lipase activity, and free 
fatty acids [23]. The nutritional changes in the composition of acidified breast milk documented by 
Erickson in vitro may have led to the in vivo growth deficiencies noted in our ALHMF population [23]. 
5. Strengths and Limitations 
5.1. Strengths 
This study is the first to quantify results of use of ALHMF in a Level IIIc NICU setting. We are 
uniquely situated to evaluate outcomes of our use of ALHMF in our patient population for several 
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important reasons. First, we initiated utilization of this product on all infants at one time. There was no 
possibility of crossover product use to decrease the validity of the data. Additionally, we used this 
product on all infants who would be eligible to receive fortified human milk, as would be expected in a 
clinical NICU practice. This makes our data very relevant and applicable to clinical NICU settings. 
Second, our clinical management of nutrition in this patient population has been published and 
remains very successful with excellent growth and low baseline rates of NEC. Not only do we manage 
nutrition care of this population very closely, but we also have a defined protocol in place so that 
infants (except for fortification method) receive the same nutrition interventions over time regardless 
of which group, PHMF or ALHMF, they received. 
Additionally, our nutrition management with additional protein added to the PHMF group makes 
the comparison of the two groups more relevant by giving them a more similar nutrient intake at 
baseline than a comparison of ALHMF and PHMF alone which compares a large difference in 
delivered protein. 
Finally, we have a very detailed nutrition documentation medical record system, Intuacare. This 
system allows for easy retrieval of detailed nutrition information including daily percentages of breast 
milk, daily caloric intake, and daily protein intake in g/kg/day. This allows for minimal reporting error 
in a retrospective study, such as this, and provides an excellent historical representation of each 
infant’s delivered nutrition. 
5.2. Limitations 
This retrospective review of a clinical trial of a commercially available acidified liquid human milk 
fortifier has several limitations including the retrospective nature of the study, and a modest sample 
size, which limits the power of some data points. These limitations were partially reduced by our 
reliance on electronic documentation for data collection and analysis. All medical documentation 
remains variable between individuals and we cannot quantify unrecorded data, but the system utilized 
allowed for complete assessment of all recorded data on each research subject. As with any study 
evaluating growth, head circumference and length measurements are also variable as length boards 
were not used and measuring tape placement may vary between nursing staff. Some subjects were 
discharged prior to 36 weeks EGA, therefore, anthropometric measurements at 36 weeks EGA were 
not available. Likewise, lab values were also unavailable for these infants and could not be included in 
data analysis. 
Alterations in human milk composition are continuous, so calculated nutrient compositions of 
fortified human milk may only serve as general estimations for our nutrient comparisons. Standard 
NICU nutrition practices are followed as consistently as possible, however feeding advancement may 
remain variable according to infant clinical status. Furthermore, the proportion of feedings as human 
milk or formula remained variable among each infant. In an ideal study, all enrolled infants would 
receive human milk only. 
Though the incidence of NEC was statistically significant, it was not powered as a primary outcome 
for this study. We also suspect that diaper dermatitis was under-recorded during this study period, as 
our clinical experience suggests that diaper dermatitis is infrequently documented in the electronic 
medical record even when infants experience more serious medical complications. However, perceived 
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worsening skin breakdown in our unit while using the ALHMF prompted development of a unit list of 
infants with diaper dermatitis. Unfortunately, not all of the infants recorded on the unit list had diaper 
dermatitis electronically documented as a medical problem. As there was no way to quantify these 
cases, these select infants were not coded positively for diaper dermatitis in this study. Therefore, our 
data analysis remains limited. 
6. Conclusions 
Use of the new ALHMF resulted in an increase in clinical complications and a decrease in growth 
as measured in both g/day and g/kg/day. To our knowledge, this is one of the first studies assessing use 
of the new ALHMF within a high acuity NICU without excluding infants with significant respiratory 
disease or low five-min APGAR scores. Further research with the ALHMF is needed to compare 
infant tolerance and outcomes among infants with a variety of gestational ages, weights, and increased 
clinical acuity. 
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